Head-to-head evidence
Disitamab Vedotin vs Trastuzumab rezetecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
Disitamab Vedotin
Developed by RemeGen Co., Ltd.
NCT04311034 · Phase 1/2 · completed
The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.
Next expected readout: June 2027 · NCT06734182 (registry estimate)
Trastuzumab rezetecan
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05482568 (registry estimate)
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Disitamab Vedotin
Developed by RemeGen Co., Ltd.
NCT04400695 · Phase 3 · recruiting
This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry.
Next expected readout: December 2026 · NCT05831878 (registry estimate)
Trastuzumab rezetecan
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: October 2026 · NCT06222879 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · Trastuzumab rezetecan's landscape